• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Sylvia Adams, Lina Kozhaya, +14 authors Sandra Demaria
  • Medicine
  • Clinical cancer research : an official journal of…
  • 2012 (First Published: 15 December 2012)
  • PURPOSE Skin metastases of breast cancer remain a therapeutic challenge. Toll-like receptor 7 agonist imiquimod is an immune response modifier and can induce immune-mediated rejection of primary skinContinue Reading
  • Reinhard Dummer, Axel Hauschild, +9 authors M Snežana Urošević
  • Medicine
  • Clinical cancer research : an official journal of…
  • 2008 (First Published: 1 February 2008)
  • PURPOSE A topical Toll-like receptor 7 (TLR7) agonist induces regression of cutaneous melanocytic neoplasms. We explored antitumor activity of a systemically administered TLR7 agonist, 852A, inContinue Reading
  • Joseph L. Jorizzo, Orit Markowitz, +4 authors Sharon F. Levy
  • Medicine
  • Journal of drugs in dermatology : JDD
  • 2010 (First Published: 1 September 2010)
  • OBJECTIVE Evaluate cryosurgery followed by 3.75% imiquimod cream to treat actinic keratoses (AK). METHODS Adults with > or =10 AKs on the face underwent cryosurgery of five to 14 lesions. SubjectsContinue Reading
  • Daniel Nathan Sauder, Michael H. Smith, Therese Senta-McMillian, Inmaculada Soria, Tze-Chiang Meng
  • Medicine
  • Antimicrobial agents and chemotherapy
  • 2003 (First Published: 1 December 2003)
  • Resiquimod is a Toll-like receptor 7 (TLR7) and TLR8 agonist that is a potent inducer of alpha interferon (IFN-alpha) and other cytokines. The effects of multiple applications of resiquimod gel wereContinue Reading
  • James Kulp, Sharon F. Levy, Melanie C. Fein, Michael Adams, John Furst, Tze-Chiang Meng
  • Medicine
  • Archives of Dermatological Research
  • 2010 (First Published: 1 September 2010)
  • Imiquimod 3.75% cream is a topical formulation of imiquimod intended for daily application to treat actinic keratoses of the entire face or balding scalp. The objective of the study was toContinue Reading